Sai Life Sciences (SAILIFE) Q4 24/25 earnings summary

Executive summary

• Fiscal 2025 saw robust growth with double-digit revenue increase, strong execution across CDMO and CRO segments, and capacity expansion, supported by the launch of a dedicated peptide research center and recognition as a Great Place to Work.

• Focus remained on technology, infrastructure, and talent investment to align with evolving client needs and deepen customer relationships globally.

• Sustainability initiatives included partnering with DHL for emission reduction and embedding digital transformation to drive efficiency.

• Audited standalone and consolidated financial results for the year ended 31 March 2025 and unaudited results for the quarter ended 31 March 2025 were approved by the Board on 13 May 2025.

• The company completed its IPO in December 2024, raising significant capital through both offer for sale and fresh issue of shares.

Financial highlights

• Revenue from operations reached INR 1,695 crores (consolidated), up 16% year-over-year from INR 1,465 crores.

• EBITDA grew 42% to INR 425 crores, with margin expanding to 25% from 20% last year.

• Profit after tax rose 105% to INR 170 crores, driven by operational improvements and cost management.

• Material margin improved to 73% in FY25 from 69% in FY24.

• CapEx for the year was INR 408 crores, focused on manufacturing and discovery expansion.

Outlook and guidance

• Long-term guidance reiterated: EBITDA margin expected to reach 28%-30% in the next two years, with revenue CAGR projected at 15%-20% over a three- to five-year period.

• CapEx for fiscal 2026 planned at INR 700 crores, with 60%-65% for manufacturing and 35% for R&D.

• Lower interest costs expected in FY26 following completion of INR 720 crores debt repayment.

• IPO proceeds are being used for debt repayment and general corporate purposes, with unutilized funds temporarily invested in deposits.

• Focus remains on expanding capacity, optimizing margins, and improving cash flow.